This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Drug Therapy, Other  • Infectious Diseases  • Bacterial Infections  • Endophthalmitis  • Drug Therapy  • Alert me on articles by topic

Christopher N. Ta, MD

Arch Ophthalmol. 2007;125(7):972-974.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Intraocular injections of therapeutic agents are becoming standard therapy for many diseases involving the retina. For example, intravitreous injections of triamcinolone acetonide are now commonly used for the treatment of macular edema due to diabetic retinopathy.^1-2 In addition, the recent approval of Macugen (Pfizer Inc, New York, New York) and Lucentis (Genentech, South San Francisco, California) by the Food and Drug Administration is expected to result in a dramatic increase in the number of intraocular injections for the treatment of macular degeneration.³

One of the most serious complications following any intraocular injection is infectious endophthalmitis. According to one study, the median visual acuity following treatment for endophthalmitis associated with triamcinolone acetonide injection in 8 patients was 20/400, with 3 patients having no light perception.⁴ Fortunately, the prevalence of endophthalmitis following intraocular injections is quite low, although the true prevalence is still unknown. The most comprehensive literature . . . [Full Text of this Article]

AUTHOR INFORMATION
Author Affiliation: Department of Ophthalmology, School of Medicine, Stanford University, Stanford, California.

RELATED ARTICLE

The Role of Topical Antibiotic Prophylaxis for Intravitreal Injections
Ingrid U. Scott and Harry W. Flynn, Jr
Arch Ophthalmol. 2007;125(7):974-976.
EXTRACT | FULL TEXT